Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
By Annsea Park, A. Iwasaki. Cell Host and Microbe, 2020
806 citations recorded by the source corpus.
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.
Subfields: Immunology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/127e7e7dedd028f3e8f46b54b313539547510a43
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Hongjie Xia
- Xuping Xie
- Zengguo Cao
- Xianwen Zhang
- J. Chen
- Hualei Wang
- Vineet D. Menachery
- Ricardo Rajsbaum
Citations in the corpus
- Evasion of Type I Interferon by SARS-CoV-2 (2020, background): “Upon infection, viral pathogen-associated molecular patterns (PAMPs) are first recognized by multiple host pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)like receptors (RLRs), cytoplasmicDNAreceptors,andnucleotidebinding and oligomeri”